Cargando…
The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma
Interleukin-2 (IL-2) therapy has been used with success in curing metastatic renal cell carcinoma and melanoma in a small minority of patients. However, the benefits can be accompanied by severe toxicity. This review of the literature discusses varying doses of IL-2 and their associated response r...
Autores principales: | Pachella, Laura A., Madsen, Lydia T., Dains, Joyce E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625627/ https://www.ncbi.nlm.nih.gov/pubmed/26557408 |
Ejemplares similares
-
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
por: Alva, Ajjai, et al.
Publicado: (2016) -
Clinical Management of Bowel Dysfunction After Low Anterior Resection for Rectal Cancer
por: Bazzell, Angela, et al.
Publicado: (2016) -
Effectiveness of Granulocyte Transfusions in Neutropenic Adult Oncology Patients: A Comprehensive Review of the Literature
por: Demla, Asha, et al.
Publicado: (2016) -
A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma
por: Monk, Paul, et al.
Publicado: (2014) -
Hormone Replacement Therapy: An Increased Risk of Recurrence and Mortality for Breast Cancer Patients?
por: Lupo, Molly, et al.
Publicado: (2015)